FDA Approves Pancreatic Cancer Pill That Doubled Survival as Trump NIH Cuts Threaten Next Drugs
Updated
Updated · ms.now · Aug 30
FDA Approves Pancreatic Cancer Pill That Doubled Survival as Trump NIH Cuts Threaten Next Drugs
2 articles · Updated · ms.now · Aug 30
Summary
Daraxonrasib won FDA approval Wednesday for metastatic pancreatic cancer after trials showed it doubled overall survival in one of the deadliest cancers.
The pill emerged from decades of KRAS research partly backed by the National Institutes of Health, which helped overturn the view that the mutation was effectively undruggable.
That breakthrough now collides with Trump administration funding cuts, health-agency firings and grant terminations that oncologists say are already delaying research and treatments.
NIH remains the largest U.S. cancer-research funder, and 99.4% of drugs approved from 2010 to 2019 traced to NIH-supported findings, underscoring the pipeline at risk.
Researchers say daraxonrasib could open a broader wave of less toxic KRAS-targeted medicines across pancreatic, colon and lung cancers—if federal support holds.
With an undruggable cancer mutation finally unlocked, what other lethal diseases might this pan-RAS inhibitor cure next?
Could a novel molecular glue finally conquer the deadliest cancer, or will tumor resistance outsmart this unprecedented breakthrough?
Daraxonrasib (Rasonque) Doubles Survival in Pancreatic Cancer: Clinical Breakthrough and the Threat of US Science Funding Cuts
Overview
The FDA’s approval of daraxonrasib (Rasonque) for metastatic pancreatic cancer is a major breakthrough, driven by strong results from the RASolute 302 trial showing significant survival benefits. The drug works by binding to cyclophilin A, forming a complex that locks onto and blocks active RAS proteins, stopping cancer growth. However, this also disrupts healthy cell renewal, leading to common side effects like skin rash. Over time, cancer cells develop resistance, so researchers are designing combination therapies to improve outcomes. Meanwhile, aggressive federal budget cuts have forced labs to close and pushed U.S. scientists abroad, threatening future cancer research and innovation.